The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with brentuximab vedotin under the National Health Act 1953, section 100 for patients with relapsed or refractory Hodgkin lymphoma.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing brentuximab vedotin.
Section 100 arrangements
This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:
- an approved private hospital
- a public participating hospital
- a public hospital.
This item isn't PBS-subsidised for public hospital in-patients.
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised brentuximab vedotin to treat relapsed or refractory Hodgkin lymphoma can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to the PBS Complex Drugs Programs.
All written applications must include the completed:
- authority prescription form or forms
- relapsed or refractory Hodgkin lymphoma - brentuximab vedotin - initial authority application form (PB205)
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised brentuximab vedotin to treat relapsed or refractory Hodgkin lymphoma can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for more information.